Compare Enovix Corporation (ENVX) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs ResMed Inc. — how do they compare? Enovix Corporation trades at $2.54 (market cap $561.79M), while ResMed Inc. trades at $225.92 (market cap $31.78B). The key difference: ResMed Inc. is far larger — about 56.6× Enovix Corporation's market cap, and ResMed Inc. pays a 1.17% dividend while Enovix Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enovix Corporation for 11 Days and ResMed Inc. for 51 Days on average.
| ENVX | RMD | |
|---|---|---|
Market Cap | $561.79M | $31.78B |
Volume | 5,898,906 | 1,128,382 |
Sector | Industrials | Health |
52-Week High | $13.19 | $277.88 |
52-Week Low | $2.50 | $182.82 |
Typical Hold Time | 11 Days | 51 Days |
Enterprise Value | $623.49M | $31.14B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $2.55, down 5.56% today, reflecting ongoing investor concerns despite recent earnings beats. The stock shows bearish technical signals with negative moving averages and oscillators. Fundamentally, the company continues to burn cash with a net income margin of -473.89% in 2026, though revenue growth remains positive at 32% year-over-year. Recent CEO transition and strategic focus on defense battery manufacturing create uncertainty about execution.
The outlook remains challenging with significant cash burn and negative profitability, though analyst consensus is bullish with a $10.75 price target representing 321% upside. Key risks include execution challenges, high cash consumption, and competitive pressures in the battery sector. The company's $552 million cash position provides runway but requires successful commercialization to justify valuation.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical outlook supported by moving averages and strong fundamentals. The company reported revenue of $5.15B in 2025, with net income of $1.40B and robust margins. Recent earnings beats and a dividend announcement highlight operational strength, while analyst consensus leans positive with a $242.70 price target.
Outlook remains favorable due to consistent EPS growth and market share gains, though risks include competitive pressures and ongoing legal investigations. The stock offers growth potential from healthcare demand tailwinds, but investors should monitor execution against guidance and macroeconomic factors affecting medical device spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
